Pfizer Corporation

Icagen, Inc.

David Simon Millan

David James Rawson

Nigel Alan Swain

Robert Ian Storer

Brian Edward Marron

Paul Anthony Stupple

Russell Andrew Lewthwaite

Serge Beaudoin

Christopher John Markworth

Christopher William West

Michael Christopher Laufersweiler

Shulan Zhou

Steven Michael Reister

Kosuke Sasaki

Alan Daniel Brown

John Paul Mathias

Andrew Simon Bell

Ian Roger Marsh

Marcel John De Groot

Christopher Phillips

Nunzio Sciammetta

Manuel Perez Pacheco

Paul Alan Glossop

David Anthony Price

Steven Matthieu Gaulier

Benjamin Scott Greener

Sebastien Rene Galan

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Y, Z, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain. 

N-sulfonylbenzamide compounds

The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

Sulfonamide derivatives

This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.

Glucocorticoid receptor agonists

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar, X, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Chemical compounds

This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes.  These compounds are inhibitors of Nav1.7.

Sulfonamide derivatives as Nav 1.7 inhibitors

A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

Growing community of inventors

Sandwich, United Kingdom

David Simon Millan